<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25069863</article-id>
      <article-id pub-id-type="pmc">4122771</article-id>
      <article-id pub-id-type="publisher-id">4720</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2407-14-543</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A late, solitary brain metastasis of epithelial ovarian carcinoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Longo</surname>
            <given-names>Raffaele</given-names>
          </name>
          <address>
            <email>raflongo@libero.it</email>
          </address>
          <xref ref-type="aff" rid="Aff30"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Platini</surname>
            <given-names>Christian</given-names>
          </name>
          <address>
            <email>c.platini@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff30"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eid</surname>
            <given-names>Nada</given-names>
          </name>
          <address>
            <email>n.eid@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff30"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Elias-Matta</surname>
            <given-names>Cl&#xE9;mence</given-names>
          </name>
          <address>
            <email>c.elias@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff30"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buda</surname>
            <given-names>Thaar</given-names>
          </name>
          <address>
            <email>t.buda@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff31"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>&#x2019;Nguyen</surname>
            <given-names>Denis</given-names>
          </name>
          <address>
            <email>d.nguyen@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff32"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Qu&#xE9;tin</surname>
            <given-names>Philippe</given-names>
          </name>
          <address>
            <email>p.quetin@chr-metz-thionville.fr</email>
          </address>
          <xref ref-type="aff" rid="Aff32"/>
        </contrib>
        <aff id="Aff30"><label/>Division of Medical Oncology, CHR Metz-Thionville, 1 All&#xE9;e du Ch&#xE2;teau, 57085 Ars-Laquenexy, France </aff>
        <aff id="Aff31"><label/>Division of Radiology, CHR Metz-Thionville, 1 All&#xE9;e du Ch&#xE2;teau, 57085 Ars-Laquenexy, France </aff>
        <aff id="Aff32"><label/>Division of Radiotherapy, CHR Metz-Thionville, 1 All&#xE9;e du Ch&#xE2;teau, 57085 Ars-Laquenexy, France </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>7</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>14</volume>
      <elocation-id>543</elocation-id>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Longo et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Brain metastasis from epithelial ovarian cancer (EOC) is very rare with a reported incidence of less than 2%. It is usually associated with a poor prognosis that is related to several factors, the most important including: single <italic>vs</italic> multiple lesions, performance status, platinum-sensitive disease, tumor grade, extracranial disease, and multimodal approach treatment. At the time of diagnosis, an extracranial disease is found in over half of patients. The most common histology is the serous type. The median time from primary diagnosis to development of cerebral lesions is directly correlated to initial tumor grade and stage. Several therapeutic approaches can be proposed, including best supportive care +/- corticosteroids, surgery, radiotherapy and chemotherapy. A multimodal therapy approach may achieve an improved outcome and should therefore be utilized whenever applicable.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We present the case of a patient with a solitary brain metastasis which appeared 11&#xA0;years after a locally advanced and aggressive EOC (FIGO stage III C) and which totally regressed after surgery and adjuvant chemotherapy. Clinically, she showed progressive headaches, decreased visual acuity, balance and memory disorders associated with a confusional state. Brain CT scan and MRI documented a solitary, necrotic lesion in the left central parietal region with an important cerebral surrounding edema and initial cranial herniation. No other extracranial metastases were observed at the PET scan. Laboratory tests were in the normal range and CA 125 was moderatly increased at 81 UI/ml. The patient underwent surgical removal of tumor lesion, post-surgical whole-brain radiotherapy (WBRT) and systemic chemotherapy with carboplatin alone for six cycles. At a follow-up of 13&#xA0;months, she is alive, in good clinical condition and tumor progression free.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>The peculiarity of this case relies on the isolated brain relapse of a BRCA-1/BRCA-2 non-mutated EOC, which is uncommon and rare, and to the very long time, of 11&#xA0;years, from diagnosis of primary cancer and development of brain metastasis. A multimodal, aggressive approach of this isolated brain metastasis led to a complete and prolonged tumor control.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Ovarian cancer</kwd>
        <kwd>Brain metastases</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Approximately 20&#x2013;40% of all cancer patients develop brain metastases with breast cancer, lung cancer and melanoma representing the most common primary tumors
[<xref ref-type="bibr" rid="CR1">1</xref>]. The reported incidence of brain metastases from epithelial ovarian cancer (EOC) is less than 2%. Brain involvement is usually associated with a poor prognosis
[<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. Several factors seem to have an impact on overall survival (OS), including single lesion, performance status, platinum-sensitive disease, tumor grade, extracranial disease, and, probably, multimodal approach but all these factors have not been evaluated and validated in prospective studies
[<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The standard treatment consists of whole-brain radiotherapy (WBRT), which improves the quality of life by a reduction of neurological symptoms and prolongs OS to 3&#x2013;6 months
[<xref ref-type="bibr" rid="CR6">6</xref>]. Patients with a good performance status, a controlled extracranial disease and a single brain lesion are generally considered for more aggressive therapeutic strategies, including surgical resection, stereotactic radiosurgery, postoperative radiation, and chemotherapy
[<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>We report an interesting case of a 63-year-old woman presenting an isolated EOC brain metastasis, 11&#xA0;years after the primary tumor treatment.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>In Jun 2001, a 51-year-old woman was submitted to radical surgery followed by 6&#xA0;cycles of systemic chemotherapy with a carboplatin/taxol regimen for a FIGO stage IIIC mixed, undifferentiated and clear-cells ovarian cancer. The follow-up was uneventful until July 2012 when an increase of the tumor marker CA 125 was observed at 46 UI/ml. A chest-abdomen and pelvic CT scan was also performed and it was negative. In December 2012, the patient was hospitalized because of progressive headaches, decreased visual acuity, balance and memory disorders associated with a confusional state. Brain CT scan and MRI documented a solitary, necrotic lesion in the left central parietal region with an important cerebral surrounding edema and initial cranial herniation (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>A-B, red arrow). A PET scan was negative. Laboratory tests were in the normal range and CA 125 was at 81 UI/ml. The SPECT MRI revealed the absence of neurological cells in the lesion leading to the hypothesis of a late, solitary ovarian metastasis (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>C, red arrow).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>A solitary brain metastasis of epithelial ovarian carcinoma (EOC). A&#x2013;B</bold>: A solitary, necrotic lesion in the left central parietal region with an important cerebral surrounding edema and initial cranial herniation (brain MRI; red arrow). <bold>C</bold>: Absence of neurological cells in the tumor lesion (SPECT MRI; red arrow). <bold>D</bold>: A metastatic poorly differentiated carcinoma (Histology). <bold>E</bold>: Cytokeratin 7 and WT1 positivity of tumor cells (Immunohistochemistry).</p></caption><graphic xlink:href="12885_2014_4720_Fig1_HTML" id="d30e331"/></fig></p>
      <p>A corticosteroid therapy was started with a progressive improvement of neurologic symptoms. In January 2013 she underwent craniotomy with radical tumor resection. Histology showed a metastatic poorly differentiated carcinoma with an immunohistochemical profile (cytokeratin 7/WT1 positive) compatible with metastasis from ovarian primary (Figure&#xA0;
<xref rid="Fig1" ref-type="fig">1</xref>D-E). A post-surgery WBRT has been performed followed by a systemic monochemotherapy by carboplatin for six cycles.</p>
      <p>A mutational analysis was also performed and it did not find any mutation of the BRCA1/BRCA2 genes.</p>
      <p>At a follow-up of 13&#xA0;months, the patient is alive, asymthomatic, in good clinical conditions and tumor progression free. The CA 125 is in the normal range (29 UI/ml).</p>
    </sec>
    <sec id="Sec3" sec-type="conclusions">
      <title>Conclusions</title>
      <p>Brain metastases from EOC are very uncommon with a reported incidence in the literature of 1&#x2013;2.5%
[<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. This incidence is probably underestimated because of the fact that brain imaging is not generally included in routine follow-up. However, from its first description in 1978 by Mayer et al.
[<xref ref-type="bibr" rid="CR8">8</xref>], a rise in incidence has been observed probably reflecting: i) an improvement of imaging techniques, leading to an earlier and more sensitive diagnosis of brain lesions; ii) a prolonged patients&#x2019; survival by a better therapeutic strategy; iii) biological mechanisms involving the blood&#x2013;brain barrier (BBB) that can either lead to an early brain implantation after its potential chemotherapy-induced imparement or avoid a drug penetration into the brain acting as a safe haven.</p>
      <p>Radiologically, brain involvement is often multiple and presents a mixed, solid-cystic form
[<xref ref-type="bibr" rid="CR9">9</xref>]. The frontal lobe is the most frequent localisation
[<xref ref-type="bibr" rid="CR9">9</xref>]. At time of diagnosis, an extracranial disease is found in over half of the patients
[<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>].</p>
      <p>About 80% of the patients present a FIGO stage III or IV at the first diagnosis of EOC
[<xref ref-type="bibr" rid="CR2">2</xref>]. The most common histology is the serous type, which is reported in over half of the cases, followed by mixed epithelial, endometrioid, adenocarcinoma, mucinous, undifferentiated and clear cell histology, all in decreasing frequency
[<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>The reported median time from primary diagnosis to development of cerebral lesions is variable and directly correlated to initial tumor grade and stage
[<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>Only two independent prognostic factors have been shown to have a relevant clinical impact: i) the presence of extracranial disease at the time of brain relapse and ii) the performance status
[<xref ref-type="bibr" rid="CR1">1</xref>]. Conflicting results have been reported with other potential factors, including "single" <italic>vs</italic> "multiple" localisations, the interval time from primary diagnosis and metastatic manifestation, tumor stage, grade, histotype, age at diagnosis of brain relapse, site of lesion, and treatment strategy
[<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. However, a recent German, multicenter, retrospective review documented, in a multivariate analysis, five negative prognostic factors, including performance status, platinum-sentive disease, tumor grading, FIGO staging, and presence of multiple <italic>vs</italic> single lesions. Other factors, such as histology, age at primary diagnosis, ascites, residual tumor at primary surgery, extracranial disease at time of brain relapse, presentation with or without headache did not directly impact on OS. A trend for significatly longer survival for the multimodal therapy was also observed
[<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      <p>Germlime mutations of BRCA-1 and -2 genes have been reported in 10% of EOC and they seem to correlate with a more aggressive behaviour and a metastatic disease
[<xref ref-type="bibr" rid="CR13">13</xref>]. Recently, several reports showed a strict correlation between BRCA-1 mutations and incidence of brain metastases in EOC
[<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>].</p>
      <p>Several therapeutic approaches can be proposed, including best supportive care +/- corticosteroids, surgery, radiotherapy and chemotherapy. When applicable, conventional neurosurgery promises the best results. In case of contraindications to surgery, inaccessibility of lesions and the presence of multiple metastases, the most commonly used individual therapy strategy is WBRT that improves neurological symptoms and prolongs median survival up to 3&#x2013;6 months
[<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>The role of systemic chemotherapy is controversial with a reported median OS up to 16&#xA0;months even when combined with surgery or radiation
[<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. These data probably reflect the impossibility to reach a high cerebrospinal fluid drug concentration with the actual cytotoxic agents most active in EOC which are unable to cross the blood&#x2013;brain barrier.</p>
      <p>Several studies have documented an increased therapeutic potential by a multimodal, more aggressive approach.</p>
      <p>Cohen et al. reported a median OS of 5.6&#xA0;months for surgery or WBRT, when these are employed individually, and of 23.1&#xA0;months after a combination of both strategies
[<xref ref-type="bibr" rid="CR6">6</xref>]. The addition of chemotherapy to surgery and radiotherapy seems to improve OS of 3&#x2013;6 months but these data derived from retrospective, small-cohorts studies and have not been prospectively validated
[<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Recently, stereotactic radiotherapy showed promising results with a remarkable median survival of 29&#xA0;months as compared to 6&#xA0;months with WBRT
[<xref ref-type="bibr" rid="CR17">17</xref>] but it is mostly applied in selected patients with no more than 3 cerebral lesions. It is now prospectively evaluating into a multimodal approach and also in patients with multiple lesions.</p>
      <p>A multimodal therapy approach may achieve an improved outcome for the patients and should therefore be used whenever applicable. The evidence available to date is pointing towards a combination of surgery and radiotherapy as the treatment modality with the best benefit to drawback ratio
[<xref ref-type="bibr" rid="CR1">1</xref>]. An additional chemotherapy can potentially improve clinical outcome in some patients, but this benefit has to be measured against possible side-effects. Further research is needed to clarify the value of chemotherapeutic agents having a potential of reaching high concentrations in the cerebrospinal fluid.</p>
      <p>In our case, the patient presented a solitary brain metastasis 11&#xA0;years after a locally advanced and aggressive EOC which totally regressed after surgery and post-surgical chemotherapy. Brain involvement was associated with a moderatly increase of tumor marker CA125. No other extracranial metastases were observed. The patient underwent a multimodal and aggressive treatment, including surgical resection of the tumor lesion, post-surgical WBRT and systemic chemotherapy with carboplatin alone for six cycles that led to a complete and prolonged tumor control.</p>
      <p>The peculiarity of this case relies on the isolated brain relapse of a BRCA-1 and BRCA-2 non-mutated EOC, which is uncommon and rare, and to the very long time, of 11&#xA0;years, from diagnosis of primary cancer and development of brain metastasis. Finally, a multimodal and aggressive approach achiewed a prolonged tumor-free survival.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interest</bold>
        </p>
        <p>The authors declare that they have no conflict of interest.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>RL has made substantial contributions to 1) conception, acquisition, analysis and interpretation of data; 2) has been involved in drafting the manuscript and revising it critically for important intellectual content; and 3) has given final approval of the version to be published. CP carried out 1) the analysis and interpretation of data; 2) has been involved in drafting the manuscript and revising it critically for important intellectual content; and 3) has given final approval of the version to be published. NE has been involved in 1) drafting the manuscript and revising it critically for important intellectual content; and 2) has given final approval of the version to be published. CEM has been involved in 1) drafting the manuscript and revising it critically for important intellectual content; and 2) has given final approval of the version to be published. TB has been involved in 1) drafting the manuscript and revising it critically for important intellectual content; and 2) has given final approval of the version to be published. DN has been involved in 1) drafting the manuscript and revising it critically for important intellectual content; and 2) has given final approval of the version to be published. PQ has been involved in 1) drafting the manuscript and revising it critically for important intellectual content; and 2) has given final approval of the version to be published. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgment</title>
      <p>We would like to thank Mrs. Nadia Ouamara for the English revision.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pietzner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oskay-Oezcelik</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>El Khalfaoui</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Boehmer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lichtenegger</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sehouli</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Brain metastases from epithelial ovarian cancer: overview and optimal management</article-title>
          <source>Anticancer Res</source>
          <year>2009</year>
          <volume>29</volume>
          <issue>7</issue>
          <fpage>2793</fpage>
          <lpage>2798</lpage>
          <pub-id pub-id-type="pmid">19596963</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pectasides</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pectasides</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Economopoulos</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Brain metastases from epithelial ovarian cancer: a review of the literature</article-title>
          <source>Oncologist</source>
          <year>2006</year>
          <volume>11</volume>
          <issue>3</issue>
          <fpage>252</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1634/theoncologist.11-3-252</pub-id>
          <pub-id pub-id-type="pmid">16549809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kolomainen</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>JMG</given-names>
            </name>
            <name>
              <surname>Badran</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>A&#x2019;Hern</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bridges</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Blake</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Barton</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kaye</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Gore</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <issue>4</issue>
          <fpage>982</fpage>
          <lpage>986</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.20.4.982</pub-id>
          <pub-id pub-id-type="pmid">11844820</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pectasides</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aravantinos</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fountzilas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kalofonos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Efstathiou</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Karina</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pavlidis</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Farmakis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Economopoulos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Dimopoulos</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature</article-title>
          <source>Anticancer Res</source>
          <year>2005</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>3553</fpage>
          <lpage>3558</lpage>
          <pub-id pub-id-type="pmid">16101179</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sehouli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pietzner</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Harter</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>M&#xFC;nstedt</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mahner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hasenburg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Camara</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Wimberger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Boehmer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Buehling</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>El Khalfaoui</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Oskay-Ozcelik</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study</article-title>
          <source>Ann Oncol</source>
          <year>2010</year>
          <volume>21</volume>
          <issue>11</issue>
          <fpage>2201</fpage>
          <lpage>2205</lpage>
          <pub-id pub-id-type="doi">10.1093/annonc/mdq229</pub-id>
          <pub-id pub-id-type="pmid">20439341</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>ZR</given-names>
            </name>
            <name>
              <surname>Suki</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Weinberg</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Marmor</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Gershenson</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Sawaya</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome</article-title>
          <source>J Neurooncol</source>
          <year>2004</year>
          <volume>66</volume>
          <issue>3</issue>
          <fpage>313</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="doi">10.1023/B:NEON.0000014516.04943.38</pub-id>
          <pub-id pub-id-type="pmid">15015663</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Soper</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Berchuck</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Oleson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dodge</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Montana</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Clarke-Pearson</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery</article-title>
          <source>J Clin Oncol</source>
          <year>1992</year>
          <volume>10</volume>
          <issue>10</issue>
          <fpage>1553</fpage>
          <lpage>1560</lpage>
          <pub-id pub-id-type="pmid">1383433</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mayer</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Berkowitz</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Central nervous system involvement by ovarian carcinoma: a complication of prolonged survival with metastatic disease</article-title>
          <source>Cancer</source>
          <year>1978</year>
          <volume>41</volume>
          <issue>2</issue>
          <fpage>776</fpage>
          <lpage>783</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(197802)41:2&lt;776::AID-CNCR2820410253&gt;3.0.CO;2-E</pub-id>
          <pub-id pub-id-type="pmid">630551</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>D&#x2019;Andrea</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Roperto</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dinia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Caroli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Salvati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferrante</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases</article-title>
          <source>Neurosurg Rev</source>
          <year>2005</year>
          <volume>28</volume>
          <issue>2</issue>
          <fpage>120</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.1007/s10143-004-0363-4</pub-id>
          <pub-id pub-id-type="pmid">15558348</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>LeRoux</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Elliott</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Tamimi</surname>
              <given-names>HK</given-names>
            </name>
          </person-group>
          <article-title>Cerebral metastases from ovarian carcinoma</article-title>
          <source>Cancer</source>
          <year>1991</year>
          <volume>67</volume>
          <issue>8</issue>
          <fpage>2194</fpage>
          <lpage>2199</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19910415)67:8&lt;2194::AID-CNCR2820670832&gt;3.0.CO;2-#</pub-id>
          <pub-id pub-id-type="pmid">2004340</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larson</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Copeland</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Malone</surname>
              <given-names>JM</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Gershenson</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Wharton</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Central nervous system metastases in epithelial ovarian carcinoma</article-title>
          <source>Obstet Gynecol</source>
          <year>1986</year>
          <volume>68</volume>
          <issue>6</issue>
          <fpage>746</fpage>
          <lpage>750</lpage>
          <pub-id pub-id-type="pmid">3024084</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cormio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cazzolla</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Resta</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Loverro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Selvaggi</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Distant metastases in ovarian carcinoma</article-title>
          <source>Int J Gynecol Cancer</source>
          <year>2003</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>125</fpage>
          <lpage>129</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1525-1438.2003.13054.x</pub-id>
          <pub-id pub-id-type="pmid">12657111</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gourley</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Michie</surname>
              <given-names>CO</given-names>
            </name>
            <name>
              <surname>Roxburgh</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yap</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Harden</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ragupathy</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Todd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Petty</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hayward</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rye</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schellens</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Lubinski</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Carmichael</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kaye</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Mackean</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ferguson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <issue>15</issue>
          <fpage>2505</fpage>
          <lpage>2511</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.25.1082</pub-id>
          <pub-id pub-id-type="pmid">20406939</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sekine</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yoshihara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Komata</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Haino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Nishino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Increased incidence of brain metastases in BRCA1-related ovarian cancers</article-title>
          <source>J Obstet Gynaecol Res</source>
          <year>2013</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>292</fpage>
          <lpage>296</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1447-0756.2012.01961.x</pub-id>
          <pub-id pub-id-type="pmid">22889437</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koul</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Loman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Malander</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ridderheim</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Two <italic>BRCA1</italic>-positive epithelial ovarian tumors with metastases to the central nervous system: a case report</article-title>
          <source>Gynecol Oncol</source>
          <year>2001</year>
          <volume>80</volume>
          <fpage>399</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="doi">10.1006/gyno.2000.6085</pub-id>
          <pub-id pub-id-type="pmid">11263939</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melichar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Urminska</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kohlova</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Nova</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cesak</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature</article-title>
          <source>Gynecol Oncol</source>
          <year>2004</year>
          <volume>94</volume>
          <issue>2</issue>
          <fpage>267</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ygyno.2004.05.026</pub-id>
          <pub-id pub-id-type="pmid">15297161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>YK</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>YS</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer</article-title>
          <source>Gynecol Oncol</source>
          <year>2008</year>
          <volume>108</volume>
          <issue>3</issue>
          <fpage>505</fpage>
          <lpage>509</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ygyno.2007.11.027</pub-id>
          <pub-id pub-id-type="pmid">18191184</pub-id>
        </element-citation>
      </ref>
      <ref-list id="BSec1">
        <title>Pre-publication history</title>
        <ref id="CR18">
          <mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/543/prepub">http://www.biomedcentral.com/1471-2407/14/543/prepub</ext-link></mixed-citation>
        </ref>
      </ref-list>
    </ref-list>
  </back>
</article>
</pmc-articleset>
